Alveolar Dead-Space Response to Activated Protein C in Acute Respiratory Distress Syndrome

We report a complicated case of acute respiratory distress syndrome (ARDS) from severe sepsis, in which we measured the ratio of physiologic dead space to tidal volume (V(D)/V(T)) with volumetric capnography prior to, during, and after therapy with human recombinant activated protein C. Previous stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respiratory care 2010-05, Vol.55 (5), p.617-622
Hauptverfasser: KALLET, Richard H, JASMER, Robert M, PITTET, Jean-François
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 622
container_issue 5
container_start_page 617
container_title Respiratory care
container_volume 55
creator KALLET, Richard H
JASMER, Robert M
PITTET, Jean-François
description We report a complicated case of acute respiratory distress syndrome (ARDS) from severe sepsis, in which we measured the ratio of physiologic dead space to tidal volume (V(D)/V(T)) with volumetric capnography prior to, during, and after therapy with human recombinant activated protein C. Previous studies hypothesized that early in ARDS, elevated V(D)/V(T) primarily reflects increased alveolar V(D), probably caused by pronounced thrombi formation in the pulmonary microvasculature. This may be particularly true when severe sepsis is the cause of ARDS. We repeatedly measured V(D)/V(T) in a 29-year-old man with sepsis-induced ARDS over the course of activated protein C therapy. Treatment with activated protein C resulted in a pronounced reduction in V(D)/V(T), from 0.55 to 0.27. Alveolar V(D) decreased from 165 mL to 11 mL (93% reduction). Activated protein C was terminated at 41 h because of gastrointestinal bleeding. When the measurement was repeated 29 h after therapy was discontinued, V(D)/V(T) had increased modestly, to 0.34, whereas alveolar V(D) had increased to 71 mL, or 43% of the pre-activated-protein-C baseline measurement. Alveolar V(T) rose from 260 mL to 369 mL and decreased slightly after termination of activated protein C (336 mL). Over the course of activated protein C therapy there was a persistent decrease in alveolar V(D) and increase in alveolar V(T), even while positive end-expiratory pressure was reduced and respiratory-system compliance decreased. Thus, improved alveolar perfusion persisted despite signs of alveolar de-recruitment. This suggests that activated protein C may have reduced microvascular obstruction. This report provides indirect evidence that microvascular obstruction may play an important role in elevated V(D)/V(T) in early ARDS caused by severe sepsis.
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_733279744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A225792865</galeid><sourcerecordid>A225792865</sourcerecordid><originalsourceid>FETCH-LOGICAL-g338t-86a103cd2d37c03caeb23fd0416917b3c525fe6a22b91175beb291f99ad4e5203</originalsourceid><addsrcrecordid>eNpt0V9rHCEQAPClNDSXS75CEUqbpw2uurvn43Jp0sJBQv685GWZ1dmcxV2v6gbu28dwF9qDIOiovxFHP2WzQgqe86oUn7MZpYzmBWfiODsJ4U-aVqKUX7JjRgWjNeez7KmxL-gseHKJoPP7DSgkdxg2bgxIoiONiuYFImpy611EM5IlSV2jpriDxkN0fksuTYgeQyD321F7N-BpdtSDDXi2H-fZ49XPh-WvfHVz_XvZrPJnzhcxX1RQUK4007xWKQDsGO81FUUli7rjqmRljxUw1smiqMsu7cuilxK0wJJRPs_Od-duvPs7YYjtYIJCa2FEN4U21clqWQuR5LedfAaLrRl7Fz2oN902jJW1ZIuqTOriA5WaxsEoN2Jv0vpBwo__EtYINq6Ds1M06REP4df9TaduQN1uvBnAb9v370jg-x5AUGB7D6My4Z9LdVR1RfkrI-qRWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733279744</pqid></control><display><type>article</type><title>Alveolar Dead-Space Response to Activated Protein C in Acute Respiratory Distress Syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>KALLET, Richard H ; JASMER, Robert M ; PITTET, Jean-François</creator><creatorcontrib>KALLET, Richard H ; JASMER, Robert M ; PITTET, Jean-François</creatorcontrib><description>We report a complicated case of acute respiratory distress syndrome (ARDS) from severe sepsis, in which we measured the ratio of physiologic dead space to tidal volume (V(D)/V(T)) with volumetric capnography prior to, during, and after therapy with human recombinant activated protein C. Previous studies hypothesized that early in ARDS, elevated V(D)/V(T) primarily reflects increased alveolar V(D), probably caused by pronounced thrombi formation in the pulmonary microvasculature. This may be particularly true when severe sepsis is the cause of ARDS. We repeatedly measured V(D)/V(T) in a 29-year-old man with sepsis-induced ARDS over the course of activated protein C therapy. Treatment with activated protein C resulted in a pronounced reduction in V(D)/V(T), from 0.55 to 0.27. Alveolar V(D) decreased from 165 mL to 11 mL (93% reduction). Activated protein C was terminated at 41 h because of gastrointestinal bleeding. When the measurement was repeated 29 h after therapy was discontinued, V(D)/V(T) had increased modestly, to 0.34, whereas alveolar V(D) had increased to 71 mL, or 43% of the pre-activated-protein-C baseline measurement. Alveolar V(T) rose from 260 mL to 369 mL and decreased slightly after termination of activated protein C (336 mL). Over the course of activated protein C therapy there was a persistent decrease in alveolar V(D) and increase in alveolar V(T), even while positive end-expiratory pressure was reduced and respiratory-system compliance decreased. Thus, improved alveolar perfusion persisted despite signs of alveolar de-recruitment. This suggests that activated protein C may have reduced microvascular obstruction. This report provides indirect evidence that microvascular obstruction may play an important role in elevated V(D)/V(T) in early ARDS caused by severe sepsis.</description><identifier>ISSN: 0020-1324</identifier><identifier>EISSN: 1943-3654</identifier><identifier>PMID: 20420733</identifier><identifier>CODEN: RECACP</identifier><language>eng</language><publisher>Irving, TX: Daedalus</publisher><subject>Acute respiratory distress syndrome ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Artificial respiration ; Biological and medical sciences ; Capnography ; Care and treatment ; Development and progression ; Dose-Response Relationship, Drug ; Emergency and intensive respiratory care ; Fatal Outcome ; Fibrinolytic Agents - administration &amp; dosage ; Fibrinolytic Agents - therapeutic use ; Follow-Up Studies ; Health aspects ; Humans ; Intensive care medicine ; Male ; Management ; Medical sciences ; Prognosis ; Protein C ; Protein C - administration &amp; dosage ; Protein C - therapeutic use ; Pulmonary Alveoli - drug effects ; Pulmonary Alveoli - physiopathology ; Respiratory Dead Space - drug effects ; Respiratory Dead Space - physiology ; Respiratory Distress Syndrome, Adult - drug therapy ; Respiratory Distress Syndrome, Adult - physiopathology ; Tidal Volume - drug effects ; Tidal Volume - physiology</subject><ispartof>Respiratory care, 2010-05, Vol.55 (5), p.617-622</ispartof><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2010 Daedalus Enterprises, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22796760$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20420733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KALLET, Richard H</creatorcontrib><creatorcontrib>JASMER, Robert M</creatorcontrib><creatorcontrib>PITTET, Jean-François</creatorcontrib><title>Alveolar Dead-Space Response to Activated Protein C in Acute Respiratory Distress Syndrome</title><title>Respiratory care</title><addtitle>Respir Care</addtitle><description>We report a complicated case of acute respiratory distress syndrome (ARDS) from severe sepsis, in which we measured the ratio of physiologic dead space to tidal volume (V(D)/V(T)) with volumetric capnography prior to, during, and after therapy with human recombinant activated protein C. Previous studies hypothesized that early in ARDS, elevated V(D)/V(T) primarily reflects increased alveolar V(D), probably caused by pronounced thrombi formation in the pulmonary microvasculature. This may be particularly true when severe sepsis is the cause of ARDS. We repeatedly measured V(D)/V(T) in a 29-year-old man with sepsis-induced ARDS over the course of activated protein C therapy. Treatment with activated protein C resulted in a pronounced reduction in V(D)/V(T), from 0.55 to 0.27. Alveolar V(D) decreased from 165 mL to 11 mL (93% reduction). Activated protein C was terminated at 41 h because of gastrointestinal bleeding. When the measurement was repeated 29 h after therapy was discontinued, V(D)/V(T) had increased modestly, to 0.34, whereas alveolar V(D) had increased to 71 mL, or 43% of the pre-activated-protein-C baseline measurement. Alveolar V(T) rose from 260 mL to 369 mL and decreased slightly after termination of activated protein C (336 mL). Over the course of activated protein C therapy there was a persistent decrease in alveolar V(D) and increase in alveolar V(T), even while positive end-expiratory pressure was reduced and respiratory-system compliance decreased. Thus, improved alveolar perfusion persisted despite signs of alveolar de-recruitment. This suggests that activated protein C may have reduced microvascular obstruction. This report provides indirect evidence that microvascular obstruction may play an important role in elevated V(D)/V(T) in early ARDS caused by severe sepsis.</description><subject>Acute respiratory distress syndrome</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Artificial respiration</subject><subject>Biological and medical sciences</subject><subject>Capnography</subject><subject>Care and treatment</subject><subject>Development and progression</subject><subject>Dose-Response Relationship, Drug</subject><subject>Emergency and intensive respiratory care</subject><subject>Fatal Outcome</subject><subject>Fibrinolytic Agents - administration &amp; dosage</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Follow-Up Studies</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Management</subject><subject>Medical sciences</subject><subject>Prognosis</subject><subject>Protein C</subject><subject>Protein C - administration &amp; dosage</subject><subject>Protein C - therapeutic use</subject><subject>Pulmonary Alveoli - drug effects</subject><subject>Pulmonary Alveoli - physiopathology</subject><subject>Respiratory Dead Space - drug effects</subject><subject>Respiratory Dead Space - physiology</subject><subject>Respiratory Distress Syndrome, Adult - drug therapy</subject><subject>Respiratory Distress Syndrome, Adult - physiopathology</subject><subject>Tidal Volume - drug effects</subject><subject>Tidal Volume - physiology</subject><issn>0020-1324</issn><issn>1943-3654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0V9rHCEQAPClNDSXS75CEUqbpw2uurvn43Jp0sJBQv685GWZ1dmcxV2v6gbu28dwF9qDIOiovxFHP2WzQgqe86oUn7MZpYzmBWfiODsJ4U-aVqKUX7JjRgWjNeez7KmxL-gseHKJoPP7DSgkdxg2bgxIoiONiuYFImpy611EM5IlSV2jpriDxkN0fksuTYgeQyD321F7N-BpdtSDDXi2H-fZ49XPh-WvfHVz_XvZrPJnzhcxX1RQUK4007xWKQDsGO81FUUli7rjqmRljxUw1smiqMsu7cuilxK0wJJRPs_Od-duvPs7YYjtYIJCa2FEN4U21clqWQuR5LedfAaLrRl7Fz2oN902jJW1ZIuqTOriA5WaxsEoN2Jv0vpBwo__EtYINq6Ds1M06REP4df9TaduQN1uvBnAb9v370jg-x5AUGB7D6My4Z9LdVR1RfkrI-qRWg</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>KALLET, Richard H</creator><creator>JASMER, Robert M</creator><creator>PITTET, Jean-François</creator><general>Daedalus</general><general>Daedalus Enterprises, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Alveolar Dead-Space Response to Activated Protein C in Acute Respiratory Distress Syndrome</title><author>KALLET, Richard H ; JASMER, Robert M ; PITTET, Jean-François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g338t-86a103cd2d37c03caeb23fd0416917b3c525fe6a22b91175beb291f99ad4e5203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acute respiratory distress syndrome</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Artificial respiration</topic><topic>Biological and medical sciences</topic><topic>Capnography</topic><topic>Care and treatment</topic><topic>Development and progression</topic><topic>Dose-Response Relationship, Drug</topic><topic>Emergency and intensive respiratory care</topic><topic>Fatal Outcome</topic><topic>Fibrinolytic Agents - administration &amp; dosage</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Follow-Up Studies</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Management</topic><topic>Medical sciences</topic><topic>Prognosis</topic><topic>Protein C</topic><topic>Protein C - administration &amp; dosage</topic><topic>Protein C - therapeutic use</topic><topic>Pulmonary Alveoli - drug effects</topic><topic>Pulmonary Alveoli - physiopathology</topic><topic>Respiratory Dead Space - drug effects</topic><topic>Respiratory Dead Space - physiology</topic><topic>Respiratory Distress Syndrome, Adult - drug therapy</topic><topic>Respiratory Distress Syndrome, Adult - physiopathology</topic><topic>Tidal Volume - drug effects</topic><topic>Tidal Volume - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KALLET, Richard H</creatorcontrib><creatorcontrib>JASMER, Robert M</creatorcontrib><creatorcontrib>PITTET, Jean-François</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KALLET, Richard H</au><au>JASMER, Robert M</au><au>PITTET, Jean-François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alveolar Dead-Space Response to Activated Protein C in Acute Respiratory Distress Syndrome</atitle><jtitle>Respiratory care</jtitle><addtitle>Respir Care</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>55</volume><issue>5</issue><spage>617</spage><epage>622</epage><pages>617-622</pages><issn>0020-1324</issn><eissn>1943-3654</eissn><coden>RECACP</coden><abstract>We report a complicated case of acute respiratory distress syndrome (ARDS) from severe sepsis, in which we measured the ratio of physiologic dead space to tidal volume (V(D)/V(T)) with volumetric capnography prior to, during, and after therapy with human recombinant activated protein C. Previous studies hypothesized that early in ARDS, elevated V(D)/V(T) primarily reflects increased alveolar V(D), probably caused by pronounced thrombi formation in the pulmonary microvasculature. This may be particularly true when severe sepsis is the cause of ARDS. We repeatedly measured V(D)/V(T) in a 29-year-old man with sepsis-induced ARDS over the course of activated protein C therapy. Treatment with activated protein C resulted in a pronounced reduction in V(D)/V(T), from 0.55 to 0.27. Alveolar V(D) decreased from 165 mL to 11 mL (93% reduction). Activated protein C was terminated at 41 h because of gastrointestinal bleeding. When the measurement was repeated 29 h after therapy was discontinued, V(D)/V(T) had increased modestly, to 0.34, whereas alveolar V(D) had increased to 71 mL, or 43% of the pre-activated-protein-C baseline measurement. Alveolar V(T) rose from 260 mL to 369 mL and decreased slightly after termination of activated protein C (336 mL). Over the course of activated protein C therapy there was a persistent decrease in alveolar V(D) and increase in alveolar V(T), even while positive end-expiratory pressure was reduced and respiratory-system compliance decreased. Thus, improved alveolar perfusion persisted despite signs of alveolar de-recruitment. This suggests that activated protein C may have reduced microvascular obstruction. This report provides indirect evidence that microvascular obstruction may play an important role in elevated V(D)/V(T) in early ARDS caused by severe sepsis.</abstract><cop>Irving, TX</cop><pub>Daedalus</pub><pmid>20420733</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0020-1324
ispartof Respiratory care, 2010-05, Vol.55 (5), p.617-622
issn 0020-1324
1943-3654
language eng
recordid cdi_proquest_miscellaneous_733279744
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Acute respiratory distress syndrome
Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Artificial respiration
Biological and medical sciences
Capnography
Care and treatment
Development and progression
Dose-Response Relationship, Drug
Emergency and intensive respiratory care
Fatal Outcome
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - therapeutic use
Follow-Up Studies
Health aspects
Humans
Intensive care medicine
Male
Management
Medical sciences
Prognosis
Protein C
Protein C - administration & dosage
Protein C - therapeutic use
Pulmonary Alveoli - drug effects
Pulmonary Alveoli - physiopathology
Respiratory Dead Space - drug effects
Respiratory Dead Space - physiology
Respiratory Distress Syndrome, Adult - drug therapy
Respiratory Distress Syndrome, Adult - physiopathology
Tidal Volume - drug effects
Tidal Volume - physiology
title Alveolar Dead-Space Response to Activated Protein C in Acute Respiratory Distress Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A55%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alveolar%20Dead-Space%20Response%20to%20Activated%20Protein%20C%20in%20Acute%20Respiratory%20Distress%20Syndrome&rft.jtitle=Respiratory%20care&rft.au=KALLET,%20Richard%20H&rft.date=2010-05-01&rft.volume=55&rft.issue=5&rft.spage=617&rft.epage=622&rft.pages=617-622&rft.issn=0020-1324&rft.eissn=1943-3654&rft.coden=RECACP&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA225792865%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733279744&rft_id=info:pmid/20420733&rft_galeid=A225792865&rfr_iscdi=true